|
1
|
Whiting DR, Guariguata L, Weil C and Shaw
J: IDF diabetes atlas: global estimates of the prevalence of
diabetes for 2011 and 2030. Diabetes Res Clin Pract. 94:311–321.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosi E, Dotta F, Jia Y and Goodman M:
Vildagliptin plus metformin combination therapy provides superior
glycaemic control to individual monotherapy in treatment-naive
patients with type 2 diabetes mellitus. Diabetes Obes Metab.
11:506–515. 2009. View Article : Google Scholar
|
|
3
|
Ligueros-Saylan M, Foley JE, Schweizer A,
Couturier A and Kothny W: An assessment of adverse effects of
vildagliptin versus comparators on the liver, the pancreas, the
immune system, the skin and in patients with impaired renal
function from a large pooled database of Phase II and III clinical
trials. Diabetes Obes Metab. 12:495–509. 2010. View Article : Google Scholar
|
|
4
|
Filozof C and Gautier JF: A comparison of
efficacy and safety of vildagliptin and gliclazide in combination
with metformin in patients with Type 2 diabetes inadequately
controlled with metformin alone: a 52-week, randomized study.
Diabet Med. 27:318–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matthews DR, Dejager S, Ahren B, et al:
Vildagliptin add-on to metformin produces similar efficacy and
reduced hypoglycaemic risk compared with glimepiride, with no
weight gain: results from a 2-year study. Diabetes Obes Metab.
12:780–789. 2010.PubMed/NCBI
|
|
6
|
Schweizer A, Dejager S, Foley JE, Shao Q
and Kothny W: Clinical experience with vildagliptin in the
management of type 2 diabetes in a patient population ≥75 years: a
pooled analysis from a database of clinical trials. Diabetes Obes
Metab. 13:55–64. 2011.PubMed/NCBI
|
|
7
|
Patel B and Shah J: Safety and efficacy of
vildagliptin: dipeptidyl peptidase-4 inhibitor. IJPRBS. 2:35–51.
2012.
|
|
8
|
Ahrén B, Schweizer A, Dejager S, Villhauer
EB, Dunning BE and Foley JE: Mechanisms of action of the dipeptidyl
peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab.
13:775–783. 2011.
|
|
9
|
Rodbard HW, Jellinger PS, Davidson JA, et
al: Statement by an American Association of Clinical
Endocrinologists/American College of Endocrinology consensus panel
on type 2 diabetes mellitus:an algorithm for glycemic control.
Endocrine Practice. 15:540–549. 2009. View Article : Google Scholar
|
|
10
|
Mathieu C: The scientific evidence:
vildagliptin and the benefits of islet enhancement. Diabetes Obes
Metab. 11(Suppl 2): S9–S17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferrannini E, Fonseca V, Zinman B, et al:
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride
in patients with type 2 diabetes mellitus inadequately controlled
on metformin monotherapy. Diabetes Obes Metab. 11:157–166. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bosi E, Camisasca RP, Collober C, Rochotte
E and Garber AJ: Effects of vildagliptin on glucose control over 24
weeks in patients with type 2 diabetes inadequately controlled with
metformin. Diabetes Care. 30:890–895. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahrén B, Pacini G, Tura A, Foley JE and
Schweizer A: Improved meal-related insulin processing contributes
to the enhancement of B-cell function by the DPP-4 inhibitor
vildagliptin in patients with type 2 diabetes. Horm Metab Res.
39:826–829. 2007.PubMed/NCBI
|
|
14
|
Bolli G, Dotta F, Rochotte E and Cohen SE:
Efficacy and tolerability of vildagliptin vs. pioglitazone when
added to metformin: a 24-week, randomized, double-blind study.
Diabetes Obes Metab. 10:82–90. 2008.PubMed/NCBI
|
|
15
|
Bolli G, Dotta F, Colin L, Minic B and
Goodman M: Comparison of vildagliptin and pioglitazone in patients
with type 2 diabetes inadequately controlled with metformin.
Diabetes Obes Metab. 11:589–595. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
D’Alessio DA, Denney AM, Hermiller LM, et
al: Treatment with the dipeptidyl peptidase-4 inhibitor
vildagliptin improves fasting Islet-cell function in subjects with
type 2 diabetes. J Clin Endocrinol Metab. 94:81–88. 2009.PubMed/NCBI
|
|
17
|
Blonde L, Dagogo-Jack S, Banerji MA, et
al: Comparison of vildagliptin and thiazolidinedione as add-on
therapy in patients inadequately controlled with metformin: results
of the GALIANT trial - a primary care, type 2 diabetes study.
Diabetes Obes Metab. 11:978–986. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ahrén B, Foley JE and Bosi E: Clinical
evidence and mechanistic basis for vildagliptin’s action when added
to metformin. Diabetes Obes Metab. 13:193–203. 2011.
|
|
19
|
Richard KR, Shelburne JS and Kirk JK:
Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin
Ther. 33:1609–1629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lukashevich V, Schweizer A, Shao Q, Groop
PH and Kothny W: Safety and efficacy of vildagliptin versus placebo
in patients with type 2 diabetes and moderate or severe renal
impairment: a prospective 24-week randomized placebo-controlled
trial. Diabetes Obes Metab. 13:947–954. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kalra S: Emerging role of dipeptidyl
peptidase-IV (DPP-4) inhibitor vildagliptin in the management of
type 2 diabetes. J Assoc Physicians India. 59:237–245.
2011.PubMed/NCBI
|
